Aurobindo Pharma plans new growth strate­gies

BioSpectrum (India) - - COMPANY NEWS -

Aurobindo Pharma would broaden prod­uct port­fo­lio in the US while en­ter­ing new mar­kets in Europe as part of its growth strat­egy over the next 3-4 years. In the US, it plans to broaden port­fo­lio through ac­cel­er­ated growth in in­jectable, OTC and higher com­plex­ity prod­ucts. On the other hand, in Europe, the com­pany is plan­ning to ex­pand pres­ence into new ge­ogra­phies such as Poland and Czech Repub­lic be­sides en­hanc­ing its po­si­tion in ex­ist­ing coun­tries such as France, Ger­many, Nether­lands, Spain and the UK. Aurobindo has been fol­low­ing a strat­egy of dif­fer­en­ti­ated pipe­line with new launches, in­clud­ing injectables, oph­thalmics, spe­cial­ity prod­ucts and con­trolled sub­stances in the US mar­ket. More­over, it has also ex­panded pres­ence in di­etary sup­ple­ment busi­ness through Na­trol, which it had ac­quired in 2014. The com­pany had posted con­sol­i­dated net rev­enue from op­er­a­tions of Rs 3,678.7 crore for the first quar­ter ended June 30, 2017-18. Out of this the US for­mu­la­tion sales were at Rs 1,694.9 crore and Europe for­mu­la­tions sales were at Rs 917.6 crore.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.